TriSalus Life Sciences, Inc.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
TLSI$2.85-11.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(unaudited, in thousands, except share and per share data)
| Three Months Ended | Nine Months Ended | |||
|---|---|---|---|---|
| September 30, 2026 | September 30, 2025 | September 30, 2026 | September 30, 2025 | |
| Revenue | $12,878 | $11,566 | $33,184 | $31,946 |
| Cost of goods sold | 1,783 | 1,906 | 4,521 | 5,203 |
| Gross profit | 11,095 | 9,660 | 28,663 | 26,743 |
| Operating expenses | ||||
| Research and development (1) | 3,190 | 5,704 | 9,543 | 12,395 |
| Sales and marketing | 10,731 | 6,839 | 29,560 | 20,736 |
| General and administrative (1) | 4,883 | 6,131 | 15,493 | 17,287 |
| Loss from operations | (7,709) | (9,014) | (25,933) | (23,675) |
| Other income (expense) | ||||
| Interest income | 382 | 170 | 1,003 | 378 |
| Interest expense | (1,560) | (1,460) | (4,486) | (4,092) |
| Change in fair value of SEPA, warrant and revenue base redemption liabilities | (650) | (2,932) | 5,819 | (4,097) |
| Change in fair value of contingent earnout liability | 740 | 2,524 | 7,146 | 2,404 |
| Other expense, net | (53) | (94) | (39) | (385) |
| Loss before income taxes | (8,850) | (10,806) | (16,490) | (29,467) |
| Income tax expense | (4) | (5) | (12) | (7) |
| Net loss | $(8,854) | $(10,811) | $(16,502) | $(29,474) |
| Series A Preferred Stock conversion inducement | — | (18,516) | — | (18,516) |
| Deemed dividend related to Series A Preferred Stock conversion | — | (11,947) | — | (11,947) |
| Net loss attributable to common stockholders | $(8,854) | $(41,274) | $(16,502) | $(59,937) |
| Basic loss per share | $(0.15) | $(0.96) | $(0.29) | $(1.72) |
| Diluted loss per share | $(0.15) | $(0.96) | $(0.29) | $(1.72) |
| Weighted-average common shares outstanding, basic | 58,473,499 | 43,057,632 | 56,128,696 | 34,858,162 |
| Weighted-average common shares outstanding, diluted | 58,473,499 | 43,057,632 | 56,128,696 | 34,858,162 |
| (1)Amounts presented in the three months ended September 30, 2025 have been revised to align expense classification for the 2025 fiscal year period. | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.